ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1701

Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road

Ertugrul Cagri Bolek 1, Enes Erul 1, Gozde Kubra Yardımcı 1, Levent Kilic 2, Ali Akdoğan 1 and Omer Karadag3, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, ankara, Turkey, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 3Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: AA-amyloidosis and proteinuria, Behcet's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Bechet’s disease (BD) is a vasculitis characterized by oral aphtae, genital ulcers, skin lesions, uveitis and with less frequent involvement of the neurological, vascular and gastrointestinal tract. Amyloidosis is an uncommon but highly morbid complication of BD. This study is aimed to investigate frequency, clinicodemographic features and disease course of amyloidosis in Behcet’s Disease.

Methods: Patients with vasculitis diagnosis have been recording at Hacettepe University Vasculitis Center (HUVAC) database since October 2014. Enrolled 451 Adult BD patients were searched in terms of clinically and histopathologically amyloidosis. Demographics, clinical features and treatment characteristics of patients were re-evaluated.

Results: Two hundred thirty seven (52.5%) patients were male and 211 (46.8%) of all patients had only mucocutaneous disease. Mean age at BD diagnosis was 30.9 ±8.2 years. Five patients (1.1%) had biopsy-proven AA-type amyloidosis diagnosis (Table). All BD-amyloidosis patients were male and presented with nephrotic-range proteinuria. Diarrhea was observed in two patients. There was no clinical evidence about familial mediterranean fever (FMF) and other rheumatic or infectious etiology for development of amyloidosis in any patient. All of five patients had genital ulceration. During follow-up time after amyloidosis diagnosis (median 51 month), end-stage kidney disease (ESKD) were developed in two patients (No: 4 and 5) and no death was observed. Interferon alpha and Tocilizumab were emerging drugs used in these patients. Proteinuria almost completely regressed in two patients (No: 2 and 3).

Conclusion: BD is one of the rare causes of the AA amyloidosis. Furthermore amyloidosis in BD is an important but it is relatively rare. Therefore other possible etiologies (e.g. FMF) should be excluded. Amyloidosis could result in life-threatening disease course. Amyloidosis-related symptoms and findings (e.g. proteinuria) may be treatable according to data from our cohort and literature. Definite predictors for development of ESRD are unknown in amyloidosis of BD. However early recognition of these patients and awareness of clinicians about this rare complication is quite important.

Demographic Features and Disease Characteristics of BD Patients with Amyloidosis


Disclosure: E. Bolek, None; E. Erul, None; G. Yardımcı, None; L. Kilic, None; A. Akdoğan, None; O. Karadag, None.

To cite this abstract in AMA style:

Bolek E, Erul E, Yardımcı G, Kilic L, Akdoğan A, Karadag O. Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/amyloidosis-in-behcets-disease-experience-of-a-vasculitis-centre-at-silk-road/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/amyloidosis-in-behcets-disease-experience-of-a-vasculitis-centre-at-silk-road/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology